Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

PubMed

Digital pathology imaging artificial intelligence in cancer research and clinical trials: An NCI workshop report.

PMID: 41476571 · 2026

JournalJournal of pathology informatics
Year2026
PMID41476571

Abstract

Digital pathology imaging (DPI) is a rapidly advancing field with increasing relevance to cancer diagnosis, research, and clinical trials through large-scale image analysis and artificial intelligence (AI) integration. Despite these advances, regulatory adoption in digital pathology (DP) has lagged; to date, only three AI/ML Software as a Medical Device tool have received FDA clearance, highlighting a validation dataset gap rather than an absence of regulatory pathways. On March 6-7, 2024, the N

Official Source

View on PubMed →

Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.